Investing.com - Truist Securities已将 Beta Bionics, Inc. (NASDAQ:BBNX) 的目标价从37.00美元下调至25.00美元，同时维持对该股的"买入"评级。新目标价仍然代表着相对于当前13.83美元的价格有显著上涨空间，该股今年迄今已下跌54.61%。

BETA Technologies, Inc. (BETA) has filed to raise $100 million in an IPO of its Class A common stock, according to SEC S-1 registration information. BETA is ...